L
9.93
0.19 (1.95%)
| Penutupan Terdahulu | 9.74 |
| Buka | 9.71 |
| Jumlah Dagangan | 1,016,108 |
| Purata Dagangan (3B) | 1,448,041 |
| Modal Pasaran | 724,764,160 |
| Harga / Buku (P/B) | 4.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| EPS Cair (TTM) | -3.31 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.67% |
| Nisbah Semasa (MRQ) | 3.41 |
| Aliran Tunai Operasi (OCF TTM) | -88.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -50.43 M |
| Pulangan Atas Aset (ROA TTM) | -42.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -80.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Lexeo Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 121.45% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Raymond James, 151.76%) | Beli |
| Median | 18.00 (81.27%) | |
| Rendah | 10.00 (HC Wainwright & Co., 0.71%) | Beli |
| Purata | 17.75 (78.75%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 8.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 13 Jan 2026 | 17.00 (71.20%) | Beli | 7.43 |
| 11 Dec 2025 | 17.00 (71.20%) | Beli | 9.80 | |
| HC Wainwright & Co. | 13 Jan 2026 | 10.00 (0.70%) | Beli | 7.43 |
| Raymond James | 18 Dec 2025 | 25.00 (151.76%) | Beli | 9.96 |
| Cantor Fitzgerald | 01 Dec 2025 | 19.00 (91.34%) | Beli | 8.92 |
| 20 Nov 2025 | 19.00 (91.34%) | Beli | 8.91 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy |
| 08 Jan 2026 | Pengumuman | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy |
| 22 Dec 2025 | Pengumuman | Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 04 Dec 2025 | Pengumuman | Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum |
| 05 Nov 2025 | Pengumuman | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |